MyChesCo on MSN
Medicus submits phase 2 study design for Teverelix to FDA
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S.
Clinical trials are losing participants. Patient-first design and decentralized models can help fix the dropout problem.
Incorporating patient voice early can reduce burden through fewer visits, simpler procedures, and selective decentralization while maintaining trial objectives. Engagement failures commonly stem from ...
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company’s proposed single ...
PointClickCare, a leading health tech company helping providers deliver exceptional care, today announced the launch of Study ...
Preserve study integrity. Resist the temptation to bolt new exploratory endpoints midstream. If an additional endpoint is ...
Clinical trials are the engine of modern cancer care, transforming scientific discoveries into new treatments that can save ...
Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of Dr. Graham C ...
“We are particularly gratified to reach concurrence with the FDA on the overall study design, endpoints, and patient populations,” said Aridis CEO Vu Truong. “This provides a clear clinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results